SG11201401286QA - Methods of inhibiting tumor growth by antagonizing il-6 receptor - Google Patents

Methods of inhibiting tumor growth by antagonizing il-6 receptor

Info

Publication number: SG11201401286QA
Authority: SG; Singapore
Prior art keywords: antagonizing; receptor; methods; tumor growth; inhibiting tumor
Prior art date: 2011-11-10

Application number

SG11201401286QA

Inventor

Li Zhang

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-10

Filing date

2012-11-09

Publication date

2014-05-29

2012-11-09 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2014-05-29 Publication of SG11201401286QA publication Critical patent/SG11201401286QA/en

Links

102000010781 Interleukin-6 Receptors Human genes 0.000 title 1
108010038501 Interleukin-6 Receptors Proteins 0.000 title 1
230000003042 antagnostic effect Effects 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
230000004614 tumor growth Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

SG11201401286QA 2011-11-10 2012-11-09 Methods of inhibiting tumor growth by antagonizing il-6 receptor SG11201401286QA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201161557939P	2011-11-10	2011-11-10
US201261609968P	2012-03-13	2012-03-13
US201261613538P	2012-03-21	2012-03-21
PCT/US2012/064311 WO2013071016A2 (en)	2011-11-10	2012-11-09	Methods of inhibiting tumor growth by antagonizing il-6 receptor

Publications (1)

Publication Number	Publication Date
SG11201401286QA true SG11201401286QA (en)	2014-05-29

Family

ID=47179020

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201401286QA SG11201401286QA (en)	2011-11-10	2012-11-09	Methods of inhibiting tumor growth by antagonizing il-6 receptor

Country Status (20)

Country	Link
US (3)	US20130122003A1 (en)
EP (1)	EP2776468B1 (en)
JP (3)	JP6144689B2 (en)
KR (1)	KR101718748B1 (en)
CN (1)	CN103930443B (en)
AR (1)	AR088671A1 (en)
AU (2)	AU2012335596B2 (en)
BR (1)	BR112014011211A2 (en)
CA (1)	CA2853836C (en)
IL (2)	IL231854A (en)
IN (1)	IN2014CN02923A (en)
JO (1)	JO3370B1 (en)
MX (1)	MX357837B (en)
MY (1)	MY163953A (en)
RU (1)	RU2648150C2 (en)
SG (1)	SG11201401286QA (en)
TW (3)	TW201806620A (en)
UY (1)	UY34444A (en)
WO (1)	WO2013071016A2 (en)
ZA (1)	ZA201402414B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3370B1 (en) *	2011-11-10	2019-03-13	Regeneron Pharma	Methods of inhibiting tumor growth by antagonizing il-6 receptor
WO2015000181A1 (en) *	2013-07-05	2015-01-08	华博生物医药技术（上海）有限公司	Novel recombinant fusion protein, preparation method therefor and use thereof
DE202014010499U1 (en)	2013-12-17	2015-10-20	Kymab Limited	Targeting of human PCSK9 for cholesterol treatment
US9017678B1 (en)	2014-07-15	2015-04-28	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
CA2953698A1 (en)	2014-06-28	2015-12-30	Kodiak Sciences Inc.	Dual pdgf/vegf antagonists
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
US20180169230A1 (en) *	2015-05-29	2018-06-21	Merrimack Pharmaceuticals, Inc.	Combination cancer therapies
RU2744860C2 (en)	2015-12-30	2021-03-16	Кодиак Сайенсиз Инк.	Antibodies and their conjugates
JP2020508436A (en)	2016-12-07	2020-03-19	プロジェニティ，インコーポレイテッド	Gastrointestinal tract detection method, apparatus and system
WO2018112237A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
KR20200140817A (en) *	2018-03-02	2020-12-16	코디악 사이언시스 인코포레이티드	IL-6 antibodies and fusion constructs and conjugates thereof
WO2019178259A2 (en)	2018-03-14	2019-09-19	Celledit Llc	Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
CN108567981A (en) *	2018-07-17	2018-09-25	漯河医学高等专科学校	Application of the antagonist of interleukin-6 in preparing inhibition Notch-1 protein expressions, treating the drug of cancer of pancreas
CN116726362A (en)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	Methods and devices for treating diseases with biologic therapeutic agents
EP3908303A4 (en) *	2019-01-07	2023-05-03	Hunan Siweikang Therapeutics Co. Ltd	Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
CA3157509A1 (en)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Methods of treating an eye disorder
EP4309722A2 (en)	2019-12-13	2024-01-24	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1341152C (en)	1988-01-22	2000-12-12	Tadamitsu Kishimoto	Receptor protein for human b cell stimulatory factor-2
US5670373A (en)	1988-01-22	1997-09-23	Kishimoto; Tadamitsu	Antibody to human interleukin-6 receptor
DE69229482T2 (en)	1991-04-25	1999-11-18	Chugai Pharmaceutical Co Ltd	RECOMBINED HUMAN ANTIBODIES AGAINST THE HUMAN INTERLEUKIN 6 RECEPTOR
US5888510A (en)	1993-07-21	1999-03-30	Chugai Seiyaku Kabushiki Kaisha	Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
CN1075387C (en)	1994-12-29	2001-11-28	中外制药株式会社	Antitumor agent potentiator comprising IL-6 antagonist
US5795695A (en)	1996-09-30	1998-08-18	Xerox Corporation	Recording and backing sheets containing linear and cross-linked polyester resins
US7396664B2 (en)	1999-06-08	2008-07-08	Regeneron Pharmaceuticals, Inc.	VEGF-binding fusion proteins and nucleic acids encoding the same
UA74146C2 (en) *	1999-06-08	2005-11-15	Редженерон Фармасьютікалс, Інк.	Modified chimeric polypeptide with improved pharmacokinetics
US7087411B2 (en) *	1999-06-08	2006-08-08	Regeneron Pharmaceuticals, Inc.	Fusion protein capable of binding VEGF
AU7824900A (en)	1999-10-07	2001-04-23	Eli Lilly And Company	Compounds and methods for inhibiting mrp1
WO2002036164A1 (en)	2000-10-27	2002-05-10	Chugai Seiyaku Kabushiki Kaisha	Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
US7595378B2 (en) *	2001-06-13	2009-09-29	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
PL1639013T3 (en) *	2003-07-02	2013-02-28	Innate Pharma	Pan-kir2dl NK-receptor antibodies and their use in diagnostic and therapy
CA2542691C (en)	2003-10-17	2013-09-24	Chugai Seiyaku Kabushiki Kaisha	Il-6 antagonist for use as mesothelioma therapeutic agent
TW200803894A (en)	2005-11-25	2008-01-16	Univ Keio	Prostate cancer therapeutic agents
CN102585002A (en) *	2006-06-02	2012-07-18	瑞泽恩制药公司	High affinity antibodies to human il-6 receptor
US8080248B2 (en)	2006-06-02	2011-12-20	Regeneron Pharmaceuticals, Inc.	Method of treating rheumatoid arthritis with an IL-6R antibody
WO2008154927A1 (en) *	2007-06-21	2008-12-24	Genmab A/S	Novel methods for treating egfr-associated tumors
US8323649B2 (en) *	2008-11-25	2012-12-04	Alderbio Holdings Llc	Antibodies to IL-6 and use thereof
EP2361096B1 (en) *	2008-11-25	2019-01-02	AlderBio Holdings LLC	Il-6-specific antibody to prevent or treat cachexia
JO3417B1 (en) *	2010-01-08	2019-10-20	Regeneron Pharma	Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
JO3370B1 (en) *	2011-11-10	2019-03-13	Regeneron Pharma	Methods of inhibiting tumor growth by antagonizing il-6 receptor

2012
- 2012-11-04 JO JOP/2012/0332A patent/JO3370B1/en active
- 2012-11-06 AR ARP120104169A patent/AR088671A1/en not_active Application Discontinuation
- 2012-11-09 WO PCT/US2012/064311 patent/WO2013071016A2/en active Application Filing
- 2012-11-09 CN CN201280055109.4A patent/CN103930443B/en active Active
- 2012-11-09 TW TW106138384A patent/TW201806620A/en unknown
- 2012-11-09 RU RU2014118739A patent/RU2648150C2/en active
- 2012-11-09 SG SG11201401286QA patent/SG11201401286QA/en unknown
- 2012-11-09 AU AU2012335596A patent/AU2012335596B2/en active Active
- 2012-11-09 MX MX2014004886A patent/MX357837B/en active IP Right Grant
- 2012-11-09 EP EP12787338.8A patent/EP2776468B1/en active Active
- 2012-11-09 CA CA2853836A patent/CA2853836C/en active Active
- 2012-11-09 KR KR1020147012146A patent/KR101718748B1/en active IP Right Grant
- 2012-11-09 MY MYPI2014000968A patent/MY163953A/en unknown
- 2012-11-09 TW TW105142150A patent/TW201716776A/en unknown
- 2012-11-09 BR BR112014011211A patent/BR112014011211A2/en not_active Application Discontinuation
- 2012-11-09 UY UY0001034444A patent/UY34444A/en unknown
- 2012-11-09 JP JP2014541298A patent/JP6144689B2/en active Active
- 2012-11-09 TW TW101141702A patent/TWI604852B/en active
- 2012-11-09 US US13/672,923 patent/US20130122003A1/en not_active Abandoned
2014
- 2014-04-01 IL IL231854A patent/IL231854A/en active IP Right Grant
- 2014-04-02 ZA ZA2014/02414A patent/ZA201402414B/en unknown
- 2014-04-17 IN IN2923CHN2014 patent/IN2014CN02923A/en unknown
- 2014-07-11 US US14/329,565 patent/US9409990B2/en active Active
2016
- 2016-07-07 US US15/204,639 patent/US20170022279A1/en not_active Abandoned
- 2016-10-30 IL IL248620A patent/IL248620A0/en unknown
2017
- 2017-01-06 JP JP2017000818A patent/JP6283754B2/en active Active
2018
- 2018-01-26 JP JP2018011135A patent/JP2018083841A/en not_active Withdrawn
- 2018-05-24 AU AU2018203666A patent/AU2018203666A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20170022279A1 (en)	2017-01-26
CA2853836A1 (en)	2013-05-16
IN2014CN02923A (en)	2015-07-03
AU2012335596B2 (en)	2018-05-17
US20130122003A1 (en)	2013-05-16
MY163953A (en)	2017-11-15
CA2853836C (en)	2019-07-23
JP6283754B2 (en)	2018-02-21
TWI604852B (en)	2017-11-11
RU2014118739A (en)	2015-12-20
IL248620A0 (en)	2016-12-29
EP2776468A2 (en)	2014-09-17
US20140322215A1 (en)	2014-10-30
KR101718748B1 (en)	2017-03-22
JP2018083841A (en)	2018-05-31
ZA201402414B (en)	2015-03-25
JP2017095489A (en)	2017-06-01
TW201332569A (en)	2013-08-16
CN103930443B (en)	2017-08-04
US9409990B2 (en)	2016-08-09
CN103930443A (en)	2014-07-16
BR112014011211A2 (en)	2017-04-25
TW201806620A (en)	2018-03-01
IL231854A (en)	2016-11-30
JP2014534237A (en)	2014-12-18
MX357837B (en)	2018-07-26
UY34444A (en)	2013-05-31
TW201716776A (en)	2017-05-16
JO3370B1 (en)	2019-03-13
AU2012335596A1 (en)	2014-05-22
WO2013071016A3 (en)	2013-07-25
RU2648150C2 (en)	2018-03-22
JP6144689B2 (en)	2017-06-07
IL231854A0 (en)	2014-05-28
AR088671A1 (en)	2014-06-25
KR20140095481A (en)	2014-08-01
WO2013071016A2 (en)	2013-05-16
AU2018203666A1 (en)	2018-06-14
MX2014004886A (en)	2014-07-09
EP2776468B1 (en)	2018-01-24

Publication	Publication Date	Title
IL248620A0 (en)	2016-12-29	Methods of inhibiting tumor growth by antagonizing il-6 receptor
HK1203513A1 (en)	2015-10-30	Methods of preparing substituted nucleotide analogs
EP2720719A4 (en)	2015-12-09	Method of selecting therapeutic indications
IL227648A0 (en)	2013-09-30	Process for the preparation of 4 - amino - 5 - fluoro -3-halo - 6 - (substituted) picolinates
IL228471A0 (en)	2013-12-31	Process for preparation of dronedarone by n-butylation
HK1199245A1 (en)	2015-06-26	Process for the preparation of 4-amino-3-chloro-5-fluoro-6- (substituted) picolinates 4--3--5--6-()-2-
IL230976A (en)	2016-09-29	Crystalline forms of cabazitaxel
HK1188684A1 (en)	2014-05-16	Process for the preparation of 4-amino-5-fluoro-3-halo-6- (substituted)picolinates 4--5--3--6-()-2-
PL2797436T3 (en)	2021-03-08	Methods for preparation of plant based beverages
EP2718304A4 (en)	2014-12-24	Method of preparing ethylene- -olefin-diene copolymer
EP2839017A4 (en)	2016-06-01	Methods of preparing para-xylene from biomass
EP2663568A4 (en)	2014-06-25	Process for preparation of acetals
ZA201402738B (en)	2017-09-27	Method for enhancing crop yields by application of trehalose
HK1187493A1 (en)	2014-04-11	Process for the preparation of 4-amino-3-chloro-5-fluoro-6- (substituted)picolinates 4--3--5--6-()-2-
GB201810013D0 (en)	2018-08-01	An improved method of preparing buprenorphine
ZA201308160B (en)	2015-01-28	Crystalline salts of asenapine
EP2694463A4 (en)	2014-10-29	Methods of treating central nervous system tumors
ZA201309713B (en)	2014-11-26	Process for the preparation of paliperidone
EP2794883A4 (en)	2015-12-02	Methods for improving crop yield
ZA201402773B (en)	2015-11-25	Use of phenylpyrazolin-3-carboxylates for improving plant yield
ZA201401439B (en)	2015-07-29	Use of 5-phenyl-or 5-benzyl-2isoxazoline-3carboxylates for improving plant yield
GB201117679D0 (en)	2011-11-23	Pre-stressed structures & methods of their manufacture
HUP1000616A2 (en)	2012-06-28	Process for preparation of rosuvastatin salt